×

Early Movers: BA, DOW, SWK, TSLA, YHOO

A trader works on the floor of the New York Stock Exchange.
Getty Images
A trader works on the floor of the New York Stock Exchange.

Check out which companies are making headlines before the bell:

Boeing—The jet maker earned $2.14 per share for the third quarter, beating estimates of $1.97. Revenue beat Street forecasts, and Boeing also raised its full year forecast and reported an increase in jet deliveries over a year ago.

Stanley Black & Decker—The tool maker beat estimates by 11 cents with third quarter profit of $1.55 per share, excluding certain items. Revenue was above Street forecasts, and it saw record profit margins in its consumer do-it-yourself segment.

Thermo Fisher Scientific—The life sciences company earned $1.71 per share for the third quarter, excluding certain items, 2 cents above estimates. Revenue was somewhat shy of analyst forecasts, and the company also cut its full-year forecast due to unfavorable currency fluctuations.

Dow Chemical—Dow earned 72 cents per share for the third quarter, 4 cents above estimates, with revenue above consensus as well. Dow was helped by higher sales in plastics and performance materials.

Biogen Idec—The company reported third quarter profit of $3.80 per share, excluding certain items, beating estimates of $3.46, with revenue above analyst forecasts. The beat comes even though sales of Biogen's best-selling multiple sclerosis drug Tecfidera fell short of forecasts.

EMC—The data storage company fell 2 cents short of estimates with ex-items earnings of 44 cents per share for the third quarter, though revenue was in line. EMC also lowered its full year earnings guidance due to currency fluctuations.

Xerox—The company beat estimates by 1 cent, earning 27 cents per share for the third quarter, but revenue was shy of estimates due to slower demand in Xerox's printing business.

Tupperware Brands (TUP) – The maker of kitchen storage products missed estimates by one cent, earning 90 cents per share for the third quarter, excluding certain items. Revenue was short of forecasts, and the company's current quarter forecast is below Street estimates as well.

Yahoo—Yahoo reported third quarter profit of 52 cents per share compared with estimates of 30 cents. Revenue was also above estimates, and the company said it was "well-positioned" for 2015.

Tesla—The automaker lost Daimler as a shareholder, with the German automaker selling its 4 percent stake. Separately, Michigan has become the fifth state to ban direct sales of Tesla autos to consumers.

Intuitive Surgical—The surgical products maker earned $3.92 per share for the third quarter, excluding certain items, 12 cents above estimates, with revenue handily beating consensus as well. The company sold 111 of its da Vinci surgical systems, compared with 96 the prior quarter and 101 in the same quarter a year earlier.

Cree—Cree fell 12 cents short of estimates with fiscal first quarter profit of 24 cents per share, excluding certain items, with sales also missing forecasts. The lighting products maker also issued a current quarter forecast shy of estimates, with sales growth weakening and costs rising.

IRobot—The company reported third quarter profit of 48 cents per share, 15 cents above estimates, and saw its sales score a sizable beat over forecasts. The maker of the Roomba automated vacuum cleaner also raised its full-year earnings forecast.

GT Advanced Technologies—GT reached a deal with Apple that will allow information about GT's bankruptcy to be unsealed, and will allow the supplier of scratch resistant sapphire to shut an Arizona factory and part ways with Apple.

Himax—Himax shares are under pressure after Google decided not to increase its 6.3 percent stake in Himax's Himax Display unit, a provider of liquid crystal display technology. Google had an option to increase its stake to 14.8 percent.

VMware—VMware is forecasting current quarter revenue mostly below Street estimates, as the software company sees a delay in a significant U.S. government deal, as well as lower overseas bookings.

Johnson & Johnson—J&J is speeding up work on an experimental Ebola vaccine, aiming to have 1 million doses available by 2015.


Questions? Comments? Email us at marketinsider@cnbc.com